Table 2.
The (adjusted) odds ratios of higher antibody levels (regardless of the threshold) up to 24 weeks post 2nd vaccine dose for IRD patients.
| Weeks post 2nd vacc. dose: (Total number of samples available for analysis) | 4 (552) | 12 (542) | 24 (513) | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Age× |
0.96
(0.94 - 0.97) |
< 0.0001 |
0.98
(0.96 - 0.99) |
0.0045 | 0.99 (0.97 -1.0) |
0.074 |
| mRNA-1273 vs BNT162b2 |
3.3
(2.4 - 4.6) |
< 0.0001 |
3.8
(2.7 - 5.4) |
< 0.0001 |
3.8
(2.7 - 5.2) |
< 0.0001 |
| Past SARS-CoV-2 infection vs none |
8.2
(4.8 - 14) |
< 0.0001 |
8.6
(5.1 - 15) |
< 0.0001 |
13
(7.2 - 22) |
< 0.0001 |
| Abatacept monotherapy* |
0.13
(0.035 - 0.45) |
0.0013 |
0.081
(0.020 - 0.32) |
0.00036 |
0.082
(0.021 - 0.32) |
0.00034 |
| cDMARD monotherapy* | 1.3 (0.66 - 2.4) |
0.49 | 1.8 (0.93 - 3.4) |
0.083 |
2.2
(1.1 - 4.4) |
0.022 |
| IL-6/17/23i monotherapy* | 0.97 (0.54 - 1.7) |
0.92 | 1.0 (0.55 - 1.9) |
0.97 | 1.0 (0.56 - 1.9) |
0.95 |
| JAKi monotherapy* |
0.37
(0.16 - 0.84) |
0.018 |
0.36
(0.15 - 0.85) |
0.020 | 0.64 (0.27 - 1.5) |
0.29 |
| Rituximab monotherapy* |
0.12
(0.022 - 0.62) |
0.012 |
0.074
(0.014 - 0.40) |
0.0025 |
0.11
(0.025 - 0.51) |
0.0046 |
| TNFi monotherapy* |
0.41
(0.26 - 0.65) |
0.00014 |
0.28
(0.18 - 0.45) |
< 0.0001 |
0.16
(0.098 - 0.26) |
< 0.0001 |
| RA vs axSpA | 1.0 (0.65 - 1.5) |
0.98 | 1.1 (0.72 - 1.7) |
0.68 | 0.89 (0.58 - 1.5) |
0.59 |
| PsA vs axSpA | 0.98 (0.64 - 1.5) |
0.93 | 0.94 (0.61 - 1.4) |
0.78 | 0.95 (0.61 - 1.5) |
0.82 |
| UA vs axSpA | 0.90 (0.48 - 1.7) |
0.75 | 1.3 (0.65 - 2.4) |
0.50 | 1.0 (0.53 – 1.9) |
0.98 |
| Abatacept combi# | 0.97 (0.14 - 6.8) |
0.98 | 0.49 (0.070 - 3.5) |
0.48 | 0.36 (0.055 - 2.4) |
0.29 |
| IL-6/17/23i combi# |
0.34
(0.12 - 0.95) |
0.039 |
0.26
(0.094 - 0.73) |
0.011 |
0.24
(0.086 - 0.68) |
0.0070 |
| JAKi combi# | 1.2 (0.31 - 4.9) |
0.77 | 1.2 (0.37 - 4.0) |
0.75 | 1.1 (0.35 - 3.6) |
0.85 |
| Rituximab combi# |
0.044
(0.0051 - 0.37) |
0.0040 |
0.091
(0.012 - 0.71) |
0.022 | 0.14
§
(0.015- 1.3) |
0.087 § |
| TNFi combi±# |
0.39
(0.23 - 0.65) |
0.00039 |
0.36
(0.22 - 0.60) |
< 0.0001 |
0.38
(0.22 - 0.64) |
0.00029 |
| Interaction of age with vaccine+ |
1.05
(1.02 - 1.07) |
0.00078 | 1.02 (0.995 - 1.05) |
0.11 |
1.03
(1.01 - 1.06) |
0.018 |
×For 1 y increase with BNT162b2. The following treatments are considered at baseline: *vs no medication (= currently on no medication). csDMARD, conventional synthetic disease-modifying antirheumatic drugs; IL-6/17/23i, interleukin 6/17/23 inhibitors; JAKi, janus kinase inhibitors; TNFi, tumor necrosis factor inhibitors. RA, rheumatoid arthritis; axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; UA, undifferentiated arthritis. Combi, combination therapy with csDMARD/csDMARD & GC; ±combination therapy with csDMARD/GC/csDMARD & GC; #vs respective monotherapy +Interaction term showing how the OR of mRNA-1273 vs BNT162b2 increased with increasing age (indicatively, at 4 and 24 weeks post 2nd vaccine dose, for every increase in age of 1 year, the odds ratio of higher antibody levels with mRNA-1273 vs BNT162b2 increased by 5% and 3%, respectively). The following treatment groups with five or fewer participants were included in the model but are not shown here: GC (glucocorticoid) monotherapy, PDE4i (phosphodiesterase-4 inhibitor) monotherapy and combination therapy, and csDMARD combination therapy. §At the time of analysis, only five samples from participants in this group were available from this timepoint.
Bold values indicate odds ratio estimates that were statistically significant.